The first drug indicated for severe alopecia areata in adults and adolescents from 12 years of age.

Alopecia areata is the second most common type of alopecia and affects both men and women, occurring in 80% of cases under the age of 40 and diagnosed in 20% of patients before the age of 18. To raise public awareness, Pfizer presented the findings of a study: “Alopecia areata in Spain: knowledge and perceptions of the disease”, which reveals the huge lack of knowledge that exists in society. When 9 out of 10 Spaniards see a child or teenager without hair, they are confused about the pathology they are suffering from, as 65% say they are being treated for cancer. In addition, the pharmaceutical company introduced a new therapeutic option for the disease: ritlecitinib, the first and only oral drug indicated for severe alopecia areata in adults and adolescents over 12 years of age. This is an important milestone for teenagers because… for the first time, they will be able to undergo a procedure that will significantly reduce hair loss. A new treatment that has enabled significantly more patients to achieve hair growth on 90% of their scalp.